Klotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock?
Monaco, Monte Carlo - March 28, 2024: 22nd Aesthetic and Anti-Aging Medicine World Congress AMWC at ... More the Grimaldi Forum. Face, Facial, Facelifting, Medicine, Beauty, Surgery, Mandoga Media Germany (Photo by Mandoga Media/picture alliance via Getty Images)
Klotho Neurosciences (KLTO) witnessed an astonishing 800% increase in stock value on June 9, 2025, after revealing positive results from pre-clinical studies. The company's investigations indicated that enhancing Klotho gene expression may significantly lessen age-related deterioration across various organs while prolonging both lifespan and healthspan. Separately, see – What's Better – Circle Stock Or Bitcoin?
The focus of Klotho's research is on the secreted protein s-KL, which has been identified as a potential anti-aging treatment owing to its wide-ranging biological impacts across various pathways linked to cellular damage, stress, and inflammation. In pre-clinical trials, the company employed an adeno-associated virus serotype 9 (AAV9) delivery vector to express the secreted KL protein isoform, successfully boosting serum s-KL levels and achieving a remarkable 20% increase in lifespan. [1]
This method tackles aging as a key risk factor that contributes to numerous health issues, such as cognitive decline, neuroinflammation, sarcopenia, and osteoporosis. The company possesses exclusive patents in the USA, Europe, and China covering this secreted splice variant of mammalian Klotho for the treatment of neurodegenerative and age-related conditions.
Even with the encouraging scientific basis, several key factors temper enthusiasm. The research is still in pre-clinical phases, which is the initial stage of drug development. The journey toward a commercially viable product necessitates extensive multi-year human trials, with no assurance of success. Historically, the vast majority of promising pre-clinical therapies do not succeed in becoming approved treatments. Financially, Klotho poses considerable risks. The company currently does not generate any revenue and has reported a negative net income of around $8 million over the past twelve months.
KLTO's stock performance illustrates the severe volatility that is characteristic of penny stocks and early-stage biotechnology firms. The stock declined from a high of over $12 in March 2024 to below $0.20 last month before the recent dramatic rise to approximately $2. These significant price fluctuations highlight the speculative nature of investing in companies that have no current revenue and unproven technologies.
While Klotho's anti-aging research embodies genuinely thrilling scientific potential, the investment comes with considerable risks. The combination of nascent science, absence of revenue, substantial cash burn, and extreme stock volatility makes KLTO a highly speculative investment, appropriate only for investors with a high-risk tolerance. Investors looking to gain exposure to pioneering healthcare advancements may want to consider diversified strategies, such as the Trefis High Quality (HQ) Portfolio, which distributes risk across multiple companies and sectors, rather than concentrating capital in individual speculative holdings. With a collection of 30 stocks, this portfolio has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a collective, HQ Portfolio stocks have yielded better returns with less risk compared to the benchmark index; offering a smoother investment experience, as evidenced in HQ Portfolio performance metrics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
44 minutes ago
- New York Times
European football revenue hit record €38bn in 2023-24 season
The growth of the European football industry continues to show little sign of slowing after collective revenues for the 2023-24 season climbed to a record €38billion (£32.2bn, $43.6bn). Deloitte, the leading accounting firm, has published its 34th Annual Review of Football Finance today and reported an eight per cent increase in turnover across the continent. Advertisement The so-called big five leagues — the top divisions from England, Spain, Italy, Germany, and France — still contribute the greatest figures, with their aggregate revenues found to have topped €20bn for the first time last season. Over a third of that sum continues to come from the Premier League's 20 clubs, who reported growth of four per cent on the previous campaign. Germany's Bundesliga was the only major European league to see a downturn in revenues, falling one per cent year on year to €3.8bn. That allowed La Liga's combined wealth to almost draw level as the closest competitor to the Premier League, with aggregate revenues enjoying a six per cent uplift in 2023-24. European football's aggregate revenues, with figures including domestic leagues and national associations, have grown consistently since the turn of the century and are forecast by Deloitte to continue in the next two years. They estimate revenues will have climbed to €39.3bn in the season that is just finishing, before heading north again to €43.1bn in 2025-26. Amid those positive projections, though, are warning signs. Deloitte's report sees small growth for the big five leagues in 2024-25, before revenues then plateau next season. That is predominantly down to the deep uncertainty over Ligue 1's broadcast rights, but projects largely flatlining numbers for Serie A and Bundesliga. Those forecasts suggest that the Premier League's place as market leader will only grow. Last season saw commercial revenues of the top 20 English clubs go beyond the £2bn mark for the first time, with matchday revenues climbing to £909m. Broadcast revenues (coming in at £3.3bn with earnings from European competitions) alone are more than any other top European league turns over in total. Premier League clubs are assured of that figure growing again next season as a new and improved domestic broadcast cycle begins in 2025-26. Deloitte forecasts the Premier League's aggregate revenues to touch almost £7bn next season. Advertisement Other patterns point to a more pragmatic approach on the continent. Clubs in the big five leagues were found to have reported an operating profit of €600m in 2023-24. Wages as a percentage of revenue also fell from 66 to 64, suggesting that lavish spending has been tempered. 'The pressure is mounting for more clubs to drive additional revenue at the same time as managing rising costs,' Tim Bridge, lead partner in the Deloitte Sports Business Group, said in a statement accompanying the report. 'More than ever, leaders and owners must recognise the great responsibility they have of managing these businesses, capturing the historic essence of a football club while honouring its unrivalled role as a community asset for generations to come.' Deloitte's report found Championship clubs had recorded revenues just shy of £1bn, but found wages had climbed significantly to £892m. That ensured 93 per cent of turnover from the 24 Championship clubs in 2023-24 was spent on wages, with 11 of the 24 clubs committing more on salaries than they generated. League Two's aggregate revenues climbed significantly to £160m, but 17 per cent of that inflated sum came from Wrexham, as they passed through the division in 2023-24 en route to League One. The greatest growth witnessed, though, came in the Women's Super League. Deloitte's report found that £65m had been generated, 34 per cent up on the previous season. All 12 WSL clubs reported income of over £1m for the first time, and forecasts estimate that total revenues for the top-flight of the English women's game will reach £100m in 2025-26.
Washington Post
an hour ago
- Washington Post
Nvidia chief calls AI ‘the greatest equalizer' — but warns Europe risks falling behind
PARIS — Will artificial intelligence save humanity — or destroy it? Lift up the world's poorest — or tighten the grip of a tech elite? Jensen Huang — the global chip tycoon widely predicted to become one of the world's first trillionaires — offered his answer on Wednesday: neither dystopia nor domination. AI, he said, is a tool for liberation.
Medscape
an hour ago
- Medscape
Fast Five Quiz: Late-Onset Pompe Disease
Multiple genetic variants have been associated with LOPD. However, the c.-32-13T>G splice site variant is found in up to 90% of adults and 50% of pediatric patients. Patients with LOPD often have compound heterozygous genotypes, with one allele carrying the common c.-32-13T>G splice-site variant and the other harboring a more deleterious GAA mutation (eg, nonsense, frameshift, or large deletion). Other variants— such as and c.1935C>A — are more commonly seen in infantile forms of Pompe disease. Learn more about the pathophysiology of LOPD. Diagnosis of LOPD typically follows a two-step approach: first, measuring GAA enzyme activity (often via dried blood spot assay) followed by confirmatory molecular genetic testing to identify pathogenic GAA variants. Although once considered a first-line diagnostic tool for LOPD, muscle biopsy is no longer preferred due to its invasive nature and the non-specificity of histologic findings. Muscle biopsy may still be considered in rare, ambiguous cases when enzyme and genetic testing are inconclusive or conflicting. CK levels might be elevated in some patients but are nonspecific and primarily serve to raise clinical suspicion. Learn more about the workup for LOPD. Enzyme replacement therapy (ERT) has significantly changed the natural history of the disease by improving survival and stabilizing motor and respiratory function. However, key limitations in skeletal muscle uptake and variability in clinical response remain. This is due to low expression of the mannose-6-phosphate receptor in muscle tissue, which hampers enzyme internalization. As a result, patients might experience a limited or plateaued response. Newer approaches, including modified ERT and gene therapy, are being developed to address this issue. High toxicity to cardiac muscle, uniform patient response, and development of cardiac hypertrophy have not been reported as key limitations. Learn more about treatment options for LOPD. NBS programs have reshaped the understanding of Pompe disease, particularly LOPD. A significant proportion of screen-positive newborns harbor genetic variants associated with LOPD, including pseudo deficiency alleles and variants of uncertain significance. These individuals are often asymptomatic at birth and might not develop symptoms for years, if at all. This has raised important clinical questions around monitoring, counseling, and when (or whether) to initiate therapy; expanded screening has also revealed that the true prevalence of LOPD might be higher than historical estimates suggested. Learn more about the management of LOPD. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication. Lead image: UCSF/Science Source
